Company profile
Agenus Inc.
NASDAQ: AGEN · Healthcare · Biotechnology
#335 of 1,418 Healthcare companies by revenue56th-percentile growth
EA Score
67BFH 67DQ 75GM 48SS 72
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ Altman-Z, growth stability
Methodology →Revenue TTM
$123.9M
Rev growth YoY (TTM)
+24.5%
Net income (FY)
-$3.1M
Employees
81
as of 2026-08-14
Market cap
$291.5M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$114.2M$114.2M2025
Net income-$3.1M-$3.1M2025
Operating income-$20.2M-$20.2M2025
Total assets$226.8M$226.8M2025
Equity-$271.1M-$271.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Non Cash Royalty Revenue99%
Other1%
By geography
UNITED STATES99%
Non-US1%
The read
What is Agenus Inc.’s revenue?
Agenus Inc. booked $114.2M in FY2025 revenue, growing 10% year over year — about the middle of the pack among Healthcare companies we track, at a -2.7% net margin.
Peers · Healthcare
Nortech Systems Incorporated71BGyre Therapeutics, Inc.72BOraSure Technologies, Inc.67BImmunityBio, Inc.58CAnika Therapeutics, Inc.74BUroGen Pharma Ltd.55CNeighbors
Middlesex →Key facts
CEOGaro H. Armen
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeNASDAQ: AGEN
Employees81
IPO date2000-02-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.